论文部分内容阅读
【lumiracoxib治疗骨关节炎与双氯芬酸等效】新的Ⅱ期研究数据显示，Novartis公司新的选择性COX-2抑制剂lumiracoxib（Prexige，原为COX189）治疗骨关节炎与最大治疗剂量的双氯芬酸等效。在双盲安慰剂对照研究中，583例骨关节炎病人随机接受4种剂量的本品（50，100或200mg，一
Lumiracoxib treats osteoarthritis equivalent to diclofenac New Phase II data show that Novartis’ new selective COX-2 inhibitor lumiracoxib (Prexige, formerly COX189) treats osteoarthritis as effective as diclofenac, the largest therapeutic dose . In a double-blind placebo-controlled study, 583 patients with osteoarthritis were randomized to receive 4 doses of this product (50, 100 or 200 mg, one